Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- JBHT +7.3%, SYF +5.3%, MS +2.7%, OFG +2.6%, PNFP +2.4%, USB +1.7%, UAL +1.4% (also authorizes new $1.5 bln share and warrant repurchase program), EQBK +1.3%, FHN +0.8%
Other news:
- TCS +34.2% (BYON and TCS announce partnership; BYON to invest $40 mln in TCS)
- NVCR +22.2% (FDA approves Novocure's Optune Lua)
- LAC +19.9% (General Motors (GM) to contribute combined $625 million in cash and letters of credit to new joint venture with Lithium Americas)
- AMPS +16.6% (formal review of strategic alternatives has been underway)
- ANGI +3.6% (names new COO)
- ELAN +2.9% (presented the abstract titled "Serologic response to core booster vaccinations in dogs treated with a novel JAK inhibitor" at the International Society for Companion Animal Infectious Diseases (ISCAID) symposium)
- ACET +2.9% (FDA has agreed to an amendment to the Company's Investigational New Drug application to evaluate ADI-001)
- SGMT +2.5% (Announces Upcoming Presentations at AASLD - The Liver Meeting 2024)
- EXAI +2.2% (announces the advancement of two additional discovery programs within its collaboration with Sanofi (SNY), with Exscientia receiving an aggregate of $15 mln in milestone payments)
- SHIP +2% (George Economou / Sphinx Investment affirmed 9% active stake; filed motion for preliminary injunction)
- CPA +1.6% (reports September traffic)
- SERV +1.6% (unveils third-generation autonomous delivery robot, which has entered manufacturing with 2,000 new units on track to be deployed in 2025 on Uber Eats platform)
- BYON +1.5% (BYON and TCS announce partnership; BYON to invest $40 mln in TCS)
- WDS +1.3% (reports Q3 production)
- GWRE +1.2% (prices offering of $600.0 mln of 1.25% convertible senior notes due 2029)
- ENLC +1.2% (confirmed changes to Board of Directors to reflect new ONEOK (OKE) controlling interest)
- PLCE +1.1% (files for subscription rights to purchase up to $90 mln in stock)
- WVE +1.1% (was notified that Takeda (TAK) did not intend to exercise and therefore elected to terminate its option for the Huntingtin target Collaboration and License Agreement)
- UNFI +1% (releases Grocery Wholesale Distribution Business presentation; provides 3-Year Financial Objectives)
- CGEM +1% (FDA cleared the Company's Investigational New Drug Application for CLN-978 and its global Phase 1 clinical trial may proceed in the U.S. to assess CLN-978)